Table of contents

2024-9-1

Fruquintinib-associated posterior reversible encephalopathy syndrome in a patient with multiply metastatic rectal cancer

2024-9-1

Rationale and design of the COPERNIC Trial: a study of on-treatment ctDNA changes in chemo-refractory colorectal cancer patients

2024-9-1

Different metabolic associations of hepatitis C with colon and rectal cancers: A 9-year nationwide population-based cohort study

2024-9-1

A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer

2024-9-1

Editorial Board

2024-9-1

The site of checkpoint in a continuous oncological evolving course of colon cancer to an obstruction phenotype decides the effects of “Incomplete” obstruction

2024-8-1

Clinical Outcomes of Elective Early Discontinuation of Immunotherapy Based on Objective Response in Microsatellite Instability-High Metastatic Colorectal Cancer

2024-8-1

An Evolving Landscape: New Therapies for Metastatic Colorectal Cancer

2024-8-1

Neoadjuvant Immunotherapy for Patients With Microsatellite Instability-High or POLE-Mutated Locally Advanced Colorectal Cancer With Bulky Tumors: New Optimization Strategy

2024-7-1

Clinical and molecular variables associated with early progression to checkpoint inhibitors in MSI-high metastatic colorectal cancer: a retrospective cohort study.

2024-7-1

Adaptive immune receptor distinctions along the colorectal polyp-tumor timelapse

2024-7-1

A comparison of cellular immune response and immunological biomarkers in laparoscopic surgery for colorectal cancer and benign disorders

2024-6-1

Effects of adjuvant chemotherapy on oncologic outcomes in patients with stage ⅡA rectal cancer above the peritoneal reflection who did not undergo preoperative chemoradiotherapy

2024-6-1

Minimally invasive surgery for colorectal cancer: Benchmarking uptake for a regional improvement programme

2024-6-1

Trifluridine/tipiracil based chemoradiation in locally advanced rectal cancer - The phase I/II TARC trial

2024-6-1

Consideration of Metastasis-Directed Therapy for Patients With Metastatic Colorectal Cancer: Expert Survey and Systematic Review

2024-6-1

Oncological outcomes and response rate after total neoadjuvant therapy for locally advanced rectal cancer: A network meta-analysis comparing induction vs consolidation chemotherapy vs standard chemoradiation

2024-6-1

Treatment of metastatic biliary cancers with irinotecan and 5-fluorouracil based chemotherapy after platinum/ gemcitabine progression: A systematic review and meta-analysis

2024-6-1

Determinants of metastatic colorectal cancer with permanent liver- limited disease

2024-6-1

The Effect of (Chemo)Radiotherapy on Enlarged Lateral Lymph Nodes in Patients With Locally Advanced Rectal Cancer

2024-6-1

Chemotherapy Rechallenge or Reintroduction compared to Regorafenib or Trifluridine/Tipiracil for pretreated metastatic colorectal cancer patients: a PROpensity ScorE analysis of tReatment beYond secoNd line (PROSERpYNa Study)

2024-6-1

Table of contents

2024-5-31

Editorial Board

2024-5-31

Explanatory role of conversion surgery as a mediator of the mortality risk difference between patients with unresectable metastatic colorectal cancer treated with first-line anti-EGFR agents versus bevacizumab

2024-5-1

Survival outcomes in patients with monobloc-resected stage IIC (pT4bN0) colon cancer: A retrospective observational cohort study

2024-5-1

KRAS G12C inhibitors in the treatment of metastatic colorectal cancer

2024-5-1

Clinical outcomes in T4 and/or N2 rectal cancer treated with neoadjuvant chemoradiotherapy; A retrospective study

2024-5-1

Use of FOLFOXIRI Plus Bevacizumab and Subsequent Therapies in Metastatic Colorectal Cancer: An Age-Stratified Analysis

2024-5-1

Peritoneal carcinomatosis in colorectal cancer: Review and update of current clinical data

2024-5-1

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Microsatellite Stable Colorectal Cancer

2024-5-1

VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Unresectable or Metastatic Colorectal Cancer in Asian Patients: A Prospective Cohort Study

2024-5-1

Complete Obstruction, a Real Risk Factor: A Comprehensive Study on Obstruction in Stage IIA Colon Cancer With Propensity Score Matching Analysis

2024-4-10

Appropriate Relevancy and Reliability of Real-World Data for the Utilization of Regulatory Submission

2024-4-1

Brazil-TNT: A randomized phase 2 trial of neo-adjuvant chemoradiation followed by FOLFIRINOX vs chemoradiation for stage II/III rectal cancer

2024-4-1

Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E

2024-4-1

Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair–Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D

2024-4-1

Potential for Metastasis and Recurrence in Colorectal Carcinoma In Situ: A Retrospective Analysis of 1069 Patients

2024-4-1

BRAF-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities

2024-4-1

Editorial Board

2024-3-1

Efficacy of Pyrotinib With/Without Trastuzumab in Treatment-Refractory, HER2-Positive Metastatic Colorectal Cancer: Result From a Prospective Observational Study

2024-3-1

Effectiveness of Biologic Agents Among Hispanic Patients With Metastatic Colorectal Cancer

2024-3-1

Optimizing Fecal Occult Blood Test (FOBT) Colorectal Cancer Screening Using Gut Bacteriome as a Biomarker

2024-3-1

Safety and efficacy of encorafenib, binimetinib, and cetuximab for BRAFV600E-mutant metastatic colorectal cancer: Results of the Japanese expanded access program

2024-3-1

Prognostic Impact of Primary Tumor Sidedness in Stage III Colorectal Cancer: Real-World Evidence from a Brazilian Cohort

2024-3-1

Adjuvant Chemotherapy for Older Patients With Stage III Colorectal Cancer: A Real-World Analysis of Treatment Recommendations, Treatment Administered and Impact on Cancer Recurrence

2024-3-1

A Phase 1 Study of Cabozantinib and Trifluridine/Tipiracil in Metastatic Colorectal Adenocarcinoma

2024-3-1

Salvage Treatment of Recurrent or Persistent Anal Squamous Cell Carcinoma: The Role of Multi-modality Therapy

2024-3-1

Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy

2024-3-1

Table of contents

2024-3-1